Moteur de recherche d’entreprises européennes
Financement de l’UE (3 932 775 €) : MARQUEURS ACOUSTIQUES POUR UNE MEILLEURE TÉLÉDÉTECTION DES DOSES DE RAYONNEMENT Hor28/08/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
MARQUEURS ACOUSTIQUES POUR UNE MEILLEURE TÉLÉDÉTECTION DES DOSES DE RAYONNEMENT
Approximately 50% of all cancer patients receive radiation therapy as part of their treatment. The aim is hereby to maximise tumor irradiation and to minimize healthy tissue irradiation. This implies a need for appropriate dosimetry strategies that can effectively measure the actual radiation dose imparted on the tumor. However, state-of-the-art dosimetry cannot quantify the dose distribution in (and around) the tumor, hereby inhibiting the full potential of radiotherapy. AMFORA aims to develop a non-invasive in-situ dosimetry system for radiation therapy with the potential of on-line dose assessment by casting ultrasound contrast agents (UCAs) into dose sensing theranostic devices. UCAs will be upgraded to injectable dose-sensitive and targeted devices that gather in tumor tissue and translate imparted radiation dosage into a modulation of their acoustic response upon ultrasound interrogation. Tailored ultrasound imaging and advanced signal processing algorithms will be developed to extract the (change in) acoustic signature of UCAs from backscatter data and to translate this information into a 2D or 3D dose distribution map. The specific objectives of this project are the design, development and pre-clinical validation of the aforementioned UCA based dosimetry system and a customised ultrasound read-out technology. Upon successful completion, AMFORA will have enabled the assessment of the effective radiation dose distribution in (and around) the tumor, offering an advanced and objective means to compare and evaluate treatment efficacy of different radiotherapy modalities. Such novel technology would revolutionize quality assurance and treatment follow up in radiotherapy, which also unmistakably will lead to increased patient safety and improved treatment protocols. Moreover, AMFORA is expected to trigger an avalanche of novel technologies for radiation therapy delivery and to pave the way for other in-vivo UCA based distributed sensing applications.
| Dosevue | 376 875 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 443 750 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 679 879 € |
| Interuniversitair Micro-Electronica Centrum | 393 521 € |
| Katholieke Universiteit Leuven | 1 563 750 € |
| Universita Degli Studi DI Roma TOR Vergata | 475 000 € |
https://cordis.europa.eu/project/id/766456
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Dosevue - Financement de l’UE (3 932 775 €) : MARQUEURS ACOUSTIQUES POUR UNE MEILLEURE TÉLÉDÉTECTION DES DOSES DE RAYONNEMENT"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
